Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified folfox6) with advanced gastric cancer patients having a good or poor performance status

Basit Öğe Kaydı
dc.authorscopusid55338103400
dc.authorscopusid55964993400
dc.authorscopusid7006046625
dc.authorscopusid55887198000
dc.authorscopusid54405522000
dc.authorscopusid19934327400
dc.authorscopusid8922379100
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorKodaz H.
dc.contributor.authorErdogan B.
dc.contributor.authorTurkmen E.
dc.contributor.authorEsenkaya A.
dc.contributor.authorUzunoglu S.
dc.contributor.authorCicin I.
dc.date.accessioned2024-06-12T10:27:54Z
dc.date.available2024-06-12T10:27:54Z
dc.date.issued2015
dc.description.abstractBackground: Combination chemotherapy of 5 fluorouracil (5-FU) and leucovorin (LV) with oxaliplatin, mainly FOLFOX regimens, has shown considerable antitumor activity and a tolerable toxicity profile in gastric cancer. The goal of this study was to retrospectively compare the efficacy and toxicity of modified FOLFOX-6 (mFOLFOX6) regimen in advanced gastric cancer (AGC) patients with good and poor performance status (PS). Materials and Methods: AGC patients receiving the mFOLFOX6 regimen including oxaliplatin 85 mg/m2, bolus of 5-FU 400 mg/m2 and LV 400 mg/m2 on the first day, followed by 2400mg/m2 of 5-FU as a continious infusion over 46 hour for first-line treatment were eligible for the study. Results: A total 58 patients with a median age of 59.5 (32-81) were included. The median follow up of the study was 9.2 months. Thirty patients (51.7%) with an ECOG PS 0-1 were assigned to the good PS arm, while 28 patients (48.3%) with ECOG PS 2 were in the poor PS arm. Overall response rates were 36.6 and 28.8%, respectively (p=0.91). Median PFS was 6.7 and 6.3 months in good PS and poor PS arms (p=0.50) and median OS was 9.6 and 10.4 months (p=0.55). As compared with good PS arm, poor PS arm was associated with more grade 3-4 neutropenia and anemia. Dose reduction and dose delays were also significantly higher. Conclusions: In this study, mFOLFOX6 was similarly effective in both arms. Although hematologic toxicity was significantly higher in patients with poor PS, it remained manageable. Our results suggest that this regimen may be an effective treatment option for AGC patients with poor PS.en_US
dc.identifier.doi10.7314/APJCP.2015.16.6.2355
dc.identifier.endpage2359en_US
dc.identifier.issn1513-7368
dc.identifier.issue6en_US
dc.identifier.pmid25824764en_US
dc.identifier.scopus2-s2.0-84929208808en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2355en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2015.16.6.2355
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16959
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFirst Line; Folfox; Gastric Cancer; Performance Statusen_US
dc.subjectAntineoplastic Agent; Fluorouracil; Folinic Acid; Oxaliplatin; Platinum Complex; Adenocarcinoma; Adult; Aged; Cancer Staging; Female; Follow Up; Human; Male; Metastasis; Middle Aged; Mortality; Pathology; Prognosis; Retrospective Study; Secondary; Stomach Neoplasms; Survival Rate; Tumor Recurrence; Very Elderly; Adenocarcinoma; Adult; Aged; Aged, 80 And Over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rateen_US
dc.titleComparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified folfox6) with advanced gastric cancer patients having a good or poor performance statusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu